TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Degree of acute pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of medication errors
Endpoint domain: Adverse events/effects
Primary endpoint: Expression of MCM-5 in the urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammation Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MR-CoNS nasal carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants affected by dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Anti-Human Antibodies (HAHAs) to lumretuzumab [RO5479599]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Grade 3 or 4 Hematologic and Nonhematologic Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of Fabry disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement of ASIA grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Facial Swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Potentially Clinically Important (PCI) Laboratory Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Potentially Clinically Important (PCI) Vital Sign Measurements and Physical Examination Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Liver Triglyceride Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Shared Decision Making Process Measure
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: AUC for glucose during OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical improvement on the Ordinal Scale for Clinical Improvement (OSCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants requiring mechanical ventilation for respiratory failure
Endpoint domain: Adverse events/effects
Primary endpoint: extent of subclinical atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Long term survival of patients
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of Agitated and Aggressive Behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious Adverse Device Effect (SADE) free rate for Sentus QP LV lead
Endpoint domain: Adverse events/effects
Primary endpoint: Serious Adverse Device Effect (SADE) free rate for Iperia ICD family
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic parameters of valsartan and rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Lawton Instrumental Activities of Daily Living Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline in Action Research Arm Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Fugl Meyer Assessment, upper extremity motor subsection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular profiles in exhaled breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving insulin independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AIMS2 Main Component Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum tolerated dose of carfilzomib
Endpoint domain: Adverse events/effects
Primary endpoint: Response Rate of Patients After 2 Courses of Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transplantation Rate of Patients After 2 Courses of Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Event-free Survival of Patients on Maintenance Randomization (Period 2)
Endpoint domain: Mortality/survival
Primary endpoint: Enrollment Rate
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in Follow Up Rate from 8 weeks post-enrollment to 16 weeks post-enrollment
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Frequency of suicidal relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in the Mean Urine Free Cortisol (mUFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 25(OH)D3 Serum Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in mental health condition
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prosthetic dislocation
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Complete Tumor Necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Re-infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of withdrawals due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Intracranial Haematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in total stigma score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in total fear score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in loneliness ordinal score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in fear of people COVID-19+ ordinal score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of CCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Scores on the Certification Examination
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: PK parameters (AUC) of IPI-145 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK parameters (Cmax) of IPI-145 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK parameters (t1/2) of IPI-145 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of morbid events
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of residual OSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: C. difficile infections
Endpoint domain: Adverse events/effects
Primary endpoint: C. difficile colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of patients with fully pelvic nerve plexus preserved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients removing indwelling catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hybridization of viral genome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Overall PSAS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complete Abortion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change from baseline up to 60 hours in supine systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline up to 60 hours in standing systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline up to 60 hours in supine diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline up to 60 hours in standing diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline up to 60 hours in pulse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of participants with pain severity scores > zero at one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with pain-related interference in multiple life domains
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of participants with neuropathic pain symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glucose profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary leakage when coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fingerstick Blood Glucose Results Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain score using visual analog scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in quality of life indices
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rates of acute and late toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of a causal diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PAC-SYM score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Magnitude of Manifest Cylinder (MRCYL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Manifest Refraction Spherical Equivalent (MRSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of LAL Implanted Eyes With BCDVA of 20/40 or Better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic classification accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Urine Tests With Negative Cannabinoid Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overexpression of C5a receptor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in time taken for 10 meter walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in microstructure of ingestive behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Halitosis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Patency at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Non-motor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differential expression of biomarkers between COVID-19 and controls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differential expression of biomarkers between severe and non-severe COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of biomarkers with disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capability for diagnosing Meconium stained Amniotic Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in Working Memory Domain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Engraftment Failure Transplant Related Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in Mean Weekly Glucose Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in surgical decision based on MRI findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Surgical Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Drug retention rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (0-48h) for VWF: RCo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With an Investigator's Global Assessment (IGA) Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malonyldiadehyde (MDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: systemic change of tissue oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distress memory scales
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Performance of diagnostic schemes for TB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Absence of Phonophobia
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of Nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of Photophobia
Endpoint domain: Adverse events/effects
Primary endpoint: transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: rethoracotomies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of frequent exacerbators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Infants and Children With Newly Diagnosed Chronic Medical Conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Infant and Child Death
Endpoint domain: Mortality/survival
Primary endpoint: Number of Infants With Ages and Stages Questionnaire-3 (ASQ-3) Score in the Black Zone for Any Domain at 9 Months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Patient-reported Symptom Response to Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average Change in Functioning in Specific Areas of Development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Average Change in Functioning in Specific Areas of Development
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average Change in Functioning in Specific Areas of Development
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to First Request of Additional Analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Childhood Autism Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reynolds Intellectual Assessment Scales
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Vineland Adaptive Behavior Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in self-efficacy on Breastfeeding Self-efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in LATCH score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast, AUC¥, and Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Trunk Control Measurement Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 9-Hole Peg Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Skin Integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Diagnostic yield of EBUS TBNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain Score (NRS: Numerical Rating Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Developmental quotient at the Mullen Scale of Early Learning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: multi-organ dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cartilage repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in the Neuropsychological Examination of Language (ENPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in phonemic fluency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in semantic fluency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 12-hour post-morning dose average FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Laboratory Changes
Endpoint domain: Adverse events/effects
Primary endpoint: Change of sensory block over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: miR-210 gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calf muscle biopsy biochemical measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased proteolytic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of OSA in metabolically-healthy and metabolically abnormal obese patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Association of OSA disease severity parameters with markers of abnormal metabolic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of sensitization against Simulect
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients with Early Treatment Failure (ETF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late Clinical Failure (LCF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Roland Morris Disability Questionnaire total score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Direct medical costs associated with low back pain
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Urinary Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change of LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of standard alcohol units consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Intrahepatic Lipid Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Telomere length in granulosa cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to differentiate between visual patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Tinnitus Perception Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with plasma viral load ≤ 50 copies HIV-RNA/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of patients with plasma HIV RNA maintained ≤ 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Absolute Millilitre (mL) Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Percent (%) Predicted FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in bleeding related outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the stimulated C-peptide response curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mediterranean diet compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women discussing preconception health
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: grade 3 or greater toxicities related to infusion of gene-modified cells
Endpoint domain: Adverse events/effects
Primary endpoint: less than 25% of patients developing grade 3 or greater non-hematopoietic toxicity or grade 4 CTCv.4 hematopoietic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: no decline in CD4 count by more than 25%, no HIV RNA more than 10,000 copies/mL; and no elevation of immune activation markers
Endpoint domain: Adverse events/effects
Primary endpoint: Safety measurement
Endpoint domain: Adverse events/effects